Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Meningioma 2Gastro-enteropancreatic neuroendocrine tumor 2Prostatic Neoplasms 1Neoplasms 1Breast Neoplasms 1Breast Cancer Metastatic 1Advanced Gastroenteropancreatic Neuroendocrine Tumor 1

Interventions

Blood Specimen Collection 38pembrolizumab 36Bevacizumab 22Surveys and Questionnaires 18Standard of Care 18Radiotherapy 18Exercise 17Carboplatin 16Nivolumab 15atezolizumab 14Cisplatin 14Drug Therapy 13Paclitaxel 12Fluorouracil 12Cyclophosphamide 12Cetuximab 12Trastuzumab 10Leucovorin 10Docetaxel 10Dexamethasone 10Pemetrexed 9Oxaliplatin 9Biopsy 9pertuzumab 8olaparib 8Temozolomide 8Panitumumab 8Observation 8Irinotecan 8abemaciclib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Neoplasms × Ga(III)-DOTATOC × Clear all
NCT06773624 2025-01-14

Use of 68Ga-DOTATOC PET/CT-enterography for Detection of the Primary Lesion in Neuroendocrine Tumors of the Small Bowel

European Institute of Oncology

Phase NA Recruiting
18 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡